Combined therapy with sorafenib significantly improved the intra-tumoral CD8+ T cell infiltration and upregulated IFN-γ expression, promoting hepatocellular carcinoma ferroptosis (110). The gene discussed is CD8A; the disease is hepatocellular carcinoma.